Von Willebrand factor is not a single molecule but a polymer — its biological power comes from assembling into enormous high-molecular-weight multimers¹¹ high-molecular-weight multimers
Ultra-large VWF strings secreted by endothelial cells after injury; these structures are the only form capable of capturing platelets under high arterial shear conditions; loss of these multimers is the defining feature of type 2A von Willebrand disease that can deploy across a damaged vessel wall and capture flowing platelets within microseconds. The A2 domain of VWF contains the cleavage site for ADAMTS13²² ADAMTS13
A disintegrin and metalloproteinase with thrombospondin motifs 13; a circulating metalloprotease that trims VWF multimers to normal size under shear; overactivity or hypersusceptibility causes loss of the largest, most hemostatically active multimers — a protease that regulates multimer size by cutting the chain. The A2 domain is normally kept tightly folded, burying the ADAMTS13 cleavage site and protecting the multimer from premature destruction. The rs61750581 S1613P substitution — a serine-to-proline change at position 1613 — replaces a flexible amino acid with proline, which kinks the local backbone and destabilizes the A2 domain fold. The result is a VWF multimer that is proteolyzed too readily, depleting the high-molecular-weight forms needed for normal hemostasis.

This variant is listed as OMIM allelic variant 613160.0009 for von Willebrand disease type 2A. As of February 2025, the ClinGen von Willebrand Disease Variant Curation Expert Panel reclassified it from pathogenic to Uncertain Significance (VUS), based on emerging criteria for VWD-specific variant interpretation. It meets PP3 (computational evidence of pathogenicity), PS4_Supporting (case enrichment), and PP4_Moderate (phenotype specificity), but does not yet have sufficient independent evidence to satisfy full pathogenicity criteria under current VWD curation rules.

The Mechanism

The VWF A2 domain normally adopts a β-propeller-like fold³³ β-propeller-like fold
A compact secondary structure with hydrophobic core that buries the ADAMTS13 binding region and scissile bond; disruption of this fold is the shared mechanism of all classical type 2A VWD group II mutations that shields the ADAMTS13 cleavage site Tyr1605–Met1606 from protease access. Under arterial shear, unfolding is regulated and transient — but type 2A A2 domain mutations constitutively destabilize this fold even at rest.

A FRET-based assay separating the N- and C-termini of the A2 domain demonstrated that 7 of 8 type 2A mutations tested caused persistent separation of the domain's termini⁴⁴ 7 of 8 type 2A mutations tested caused persistent separation of the domain's termini
Lynch et al., PLoS One 2017 — mutations that separate N- and C-termini promote an open conformation that exposes ADAMTS13 binding and scissile bond sites constitutively, producing a constitutively open conformation that exposes the ADAMTS13 binding and scissile sites. Earlier work confirmed that 11 of 13 A2 domain VWD type 2A mutations increased specific ADAMTS13 proteolysis⁵⁵ 11 of 13 A2 domain VWD type 2A mutations increased specific ADAMTS13 proteolysis
Hassenpflug et al., Blood 2006 — ADAMTS13 susceptibility correlated directly with in vivo multimer loss seen in patient plasma, and that the degree of proteolytic susceptibility correlated directly with the degree of HMWM loss observed in patient plasma.

An in vivo rat model demonstrated that VWF carrying the S1613P mutation undergoes accelerated proteolysis in vivo resulting in loss of high-molecular-weight multimers⁶⁶ accelerated proteolysis in vivo resulting in loss of high-molecular-weight multimers
Stoddart et al., Blood 1996 — the only published experimental evidence specifically characterizing S1613P in a living model; shows the mutation recapitulates the type 2A phenotype with appearance of satellite proteolytic fragments, while overall VWF clearance rates remain comparable to normal protein, meaning the functional deficit is selective: only the large, hemostatically active multimers are lost.

The Evidence

The variant was originally documented as a pathogenic VWD type 2A cause in OMIM based on early molecular characterization and family studies. A recent Thai multicenter study⁷⁷ Thai multicenter study
Lauhasurayotin et al., J Clin Pathol 2024 — 15 patients with type 2 or type 3 VWD genotyped by whole exome sequencing; p.Ser1613Pro identified among previously described mutations using whole exome sequencing identified p.Ser1613Pro among known pathogenic VWF mutations in VWD patients, confirming its presence in affected individuals across populations.

The February 2025 ClinGen reclassification to VUS reflects the evolution of variant interpretation criteria for VWD, not evidence of benignity. The variant has no functional counterevidence — all experimental data support pathogenicity — but specific evidence thresholds under the formal VWD curation rules are not yet fully met. Clinicians encountering this variant in the context of a confirmed bleeding phenotype should treat it as a strong candidate for clinical significance pending future reclassification.

Type 2A VWD — the disease associated with this variant — manifests as mucocutaneous bleeding including epistaxis, easy bruising, heavy menstrual bleeding, and post-surgical hemorrhage⁸⁸ mucocutaneous bleeding including epistaxis, easy bruising, heavy menstrual bleeding, and post-surgical hemorrhage
Seidizadeh et al., Semin Thromb Hemost 2026 — comprehensive clinical update on type 2A VWD. Laboratory hallmarks include a reduced VWF:RCo/VWF:Ag ratio (platelet-binding activity disproportionately lower than antigen level), reduced VWF:CB/VWF:Ag ratio, and selective loss of high- and intermediate-molecular-weight multimers on gel electrophoresis.

Practical Implications

Anyone carrying a G allele at rs61750581 with a personal or family history of unusual bleeding should pursue hematology evaluation. Diagnostic workup should include VWF antigen, VWF ristocetin cofactor activity, VWF collagen binding, FVIII:C, and VWF multimer analysis — the full type 2A laboratory panel. A DDAVP (desmopressin) responsiveness test is appropriate before any procedure, as type 2A heterozygotes can show a transient but often insufficient response⁹⁹ type 2A heterozygotes can show a transient but often insufficient response
Michiels & van Vliet, Acta Haematol 2009 — complete response in mild type 2A lasts only hours; inadequate for surgical prophylaxis in most patients. VWF concentrates containing both VWF and FVIII (Humate-P, Wilate, Vonvendi) are the standard treatment for major bleeding events and surgical prophylaxis.

Women with this variant are at particular risk for heavy menstrual bleeding, which often precedes formal VWD diagnosis by years and significantly impacts quality of life. Menorrhagia in VWD carriers is managed with tranexamic acid, hormonal therapies, or VWF concentrates for severe episodes.

Interactions

VWF S1613P interacts with the general VWF expression level: individuals with an additional low-VWF variant in the other allele may have more pronounced bleeding phenotypes than those with a single functional copy of normal VWF. Blood group O is a well-established environmental modifier — O type individuals have 25–35% lower plasma VWF levels than non-O individuals, which can worsen bleeding phenotype in anyone with a heterozygous VWF functional variant. Blood group O status should be noted when evaluating type 2A carriers clinically.

PXK¹¹ PXK
PX domain containing serine/threonine kinase like; a protein containing a phox homology (PX) domain that binds phosphoinositide lipids on endosomal membranes, positioning it in the trafficking machinery that sorts internalized receptors for recycling or degradation is a gene most people have never heard of — yet a variant within its intron has appeared consistently in genome-wide association scans for systemic lupus erythematosus (SLE) in European populations. The rs6445975 G allele was one of four loci with genome-wide significant replication in the landmark 2008 SLEGEN consortium study, placing PXK alongside more familiar SLE genes like ITGAM and STAT4. What makes PXK biologically interesting is its proposed role in controlling how immune cells terminate signalling after receptor engagement — a cellular housekeeping function with outsized consequences when disrupted in autoimmune contexts.

The Mechanism

PXK's PX domain binds phosphatidylinositol 3-phosphate (PtdIns3P)²² phosphatidylinositol 3-phosphate (PtdIns3P)
A phospholipid lipid enriched on the cytoplasmic face of early endosomes; serves as a docking signal for proteins involved in vesicle trafficking, autophagy, and receptor sorting, the signature lipid of early endosomes. This positions PXK in the endosomal sorting machinery — the cellular system that decides, after a surface receptor is internalized, whether it is recycled back to the cell surface or directed to the lysosome for degradation. Epidermal growth factor receptor (EGFR) was identified as one cargo whose degradation is regulated by proteins in the PtdIns3P-binding family that includes PXK, based on siRNA screening data.

The immune relevance is that B-cell receptor (BCR) internalization follows a mechanistically similar endosomal sorting pathway. When the BCR binds antigen, it is rapidly internalized and trafficked through endosomes for antigen processing and presentation. The efficiency of this internalization — and therefore the strength and duration of the resulting immune activation — is regulated by the same PtdIns3P-dependent endosomal machinery in which PXK participates. Reduced or altered PXK function could impair the timely termination of BCR signalling, allowing prolonged immune activation. In lupus, where B cells are already hyperactivated and produce pathogenic autoantibodies, any genetic variant that prolongs BCR signalling is a plausible contributor to disease susceptibility.

rs6445975 sits in an intron of PXK, suggesting it acts as a regulatory variant — altering expression levels or splicing of PXK isoforms in specific immune cell types rather than changing the protein sequence directly. The exact functional consequence at the molecular level has not been characterised in published eQTL studies, making the mechanistic link to BCR trafficking inferential rather than directly demonstrated.

The Evidence

The variant was first identified in the landmark 2008 SLEGEN genome-wide scan³³ landmark 2008 SLEGEN genome-wide scan led by Harley and colleagues, which examined 720 women with SLE plus 2,337 controls in the discovery cohort, with replication in a further 1,846 cases and 1,825 controls. PXK (along with ITGAM, KIAA1542, and other loci) showed evidence of association with replication across the study cohorts.

The most precise quantification comes from a 2012 meta-analysis by Lee et al.⁴⁴ 2012 meta-analysis by Lee et al. synthesising 13 studies: the rs6445975 G allele was associated with SLE at OR 1.151 (95% CI 1.086–1.291, p=1.8×10⁻⁶) in the overall population, with a stronger signal in European subgroups (OR 1.198, 95% CI 1.118–1.285, p=3.4×10⁻⁷). Notably, the Asian subgroup showed no significant association — a finding replicated independently⁵⁵ replicated independently in 910 Hong Kong Chinese SLE patients (OR 1.06, p=0.36) and Korean patients⁶⁶ Korean patients (OR 1.06, p=0.57). This population specificity is consistent with different linkage disequilibrium⁷⁷ linkage disequilibrium
The non-random association of alleles at two or more loci; a tagging SNP may associate strongly with a causal variant in one population but not another if LD patterns differ across ancestries (LD) structure around the locus across ancestries.

The strongest per-genotype effect sizes come from a 2022 Iranian case-control study⁸⁸ 2022 Iranian case-control study (110 SLE patients, 115 controls): GG homozygotes showed an OR of 7.5 versus TT (95% CI 3.47–17.07), and G allele carriers overall had a 3.55-fold elevated risk. The G allele also correlated with elevated inflammatory markers (CRP, ESR), anti-dsDNA antibody levels, complement consumption (C3/C4 abnormalities), renal involvement, and skin lesions. A Chinese cohort study⁹⁹ Chinese cohort study reinforced the autoantibody connection even in a population where overall SLE risk was not significantly elevated: the G allele was significantly associated with anti-Smith (OR 1.95), anti-Ro (OR 1.69), and anti-La (OR 1.86) antibodies — suggesting that PXK influences the specificity and breadth of autoantibody production independently of overall disease susceptibility.

The evidence level is moderate: the association is consistently replicated in European populations across multiple independent cohorts and a meta-analysis, the OR per allele (~1.15–1.2) is modest but statistically robust, and the biological mechanism (endosomal receptor trafficking) is plausible. However, the causal variant has not been identified, eQTL studies have not definitively linked rs6445975 to PXK expression, and the Asian non-replication raises questions about whether rs6445975 is the causal variant or a tagging SNP in partial LD with the functional locus.

Practical Implications

For G allele carriers — particularly those of European ancestry — the practical implications focus on early detection and proactive monitoring for early lupus features, rather than on any specific nutrient or supplement intervention. SLE is an episodic, multi-system disease whose early signs (photosensitivity, butterfly rash, joint pain, unexplained fatigue, serositis) are often attributed to other causes for years before diagnosis. The OR of ~1.15–1.2 per G allele is modest in isolation, but GG homozygotes appear to carry a substantially higher burden in Middle Eastern cohorts. Any G allele carrier with a first-degree relative with lupus, or with recurrent unexplained symptoms across multiple organ systems, has grounds to request early ANA (antinuclear antibody) screening.

Hydroxychloroquine is the cornerstone treatment for SLE and has been shown to reduce disease flares, prevent organ damage, and improve survival. Carriers of elevated-risk genotypes who are diagnosed with SLE or an undifferentiated connective tissue disease should be aware that early initiation of hydroxychloroquine is recommended by ACR/EULAR guidelines.

Interactions

The PXK locus exists within a broader landscape of SLE genetic susceptibility. STAT4 (rs7574865)¹⁰¹⁰ STAT4 (rs7574865) is one of the most strongly replicated SLE risk loci (OR ~1.5–1.7), acting through interferon-γ signalling in T cells. PTPN22 (rs2476601)¹¹¹¹ PTPN22 (rs2476601) is a well-established autoimmune risk variant disrupting T-cell and B-cell receptor signalling thresholds, also in the GeneOps database. BLK (rs13277113)¹²¹² BLK (rs13277113) encodes a B-lymphocyte kinase directly involved in BCR signalling — the same pathway that PXK's endosomal role putatively modulates. Carrying multiple SLE risk alleles across STAT4, BLK, PTPN22, and PXK represents an additive polygenic risk burden significantly exceeding any single locus. No specific compound action has been formally documented for PXK + BLK, but the biological logic of convergent BCR-pathway disruption is strong.

Your kidneys filter roughly 70% of the uric acid your body excretes each day, and the SLC2A9 gene — encoding the GLUT9 transporter¹¹ GLUT9 transporter
Glucose Transporter 9, a voltage-sensitive high-capacity urate transporter expressed on the basolateral membrane of the renal proximal tubule — is the single most important genetic regulator of how efficiently that process happens. rs6852441 is an intronic variant that tags a regulatory haplotype within this gene, with a population frequency pattern that mirrors the established risk architecture of the SLC2A9 locus: high risk-allele frequency in East Asians (where gout prevalence is greatest), low risk-allele frequency in Africans (where urate-related disease has historically been lower).

The Mechanism

rs6852441 lies within an intron of SLC2A9 and does not alter the GLUT9 protein sequence. Its functional significance, like other established intronic SLC2A9 variants (rs11942223, rs6815001, rs6814664), is regulatory: it tags a haplotype block that influences the expression, splicing, or basolateral trafficking of GLUT9 in renal proximal tubule cells. GLUT9 operates as a high-capacity electrogenic urate transporter, exchanging intracellular urate for extracellular glucose or fructose across the basolateral membrane. Variants on the risk haplotype appear to reduce net urate clearance, shifting the steady-state serum urate upward.

The C allele at rs6852441 (the GRCh38 reference) is the risk haplotype tag, found at approximately 90% frequency in East Asian populations — where gout incidence is among the highest globally — and at only about 38% in African populations, where urate-related disease has been lower. This inverse population gradient is consistent with the direction of effect seen for other established SLC2A9 intronic risk haplotype markers at this locus (Wei et al., 2014)²² (Wei et al., 2014).

The Evidence

SLC2A9 as the major urate locus: Two landmark 2008 Nature Genetics studies simultaneously established SLC2A9 as the most significant genetic determinant of serum uric acid in Europeans, with intronic variants explaining 1.7–5.3% of serum urate variance overall and up to 6% in women (Vitart et al., 2008)³³ (Vitart et al., 2008); (Döring et al., 2008)⁴⁴ (Döring et al., 2008). Carriers of risk alleles at SLC2A9 intronic variants show consistently higher serum uric acid across European, American Indian, Mexican American, and East Asian populations (Voruganti et al., 2013)⁵⁵ (Voruganti et al., 2013).

Complex local architecture: Detailed mapping of the 4p16.1 region by Wei et al. (2014) found that a five-SNP model incorporating marginal effects and epistatic interactions explained an additional 1.5% of serum urate variance beyond the lead SNP alone (Wei et al., 2014)⁶⁶ (Wei et al., 2014). The epistatically interacting SNPs are enriched at active enhancer chromatin marks in hepatic and blood cell lines, supporting a transcriptional regulation mechanism — consistent with rs6852441's intronic location at this locus.

Gout association: SLC2A9 intronic risk-allele carriers show elevated gout risk across multiple ethnic populations. Hollis-Moffatt et al. (2009) confirmed that major-allele genotypes at multiple SLC2A9 intronic variants were associated with gout in Māori, Pacific Island, and Caucasian case-control samples (OR >2.0 in Māori and Pacific groups) (Hollis-Moffatt et al., 2009)⁷⁷ (Hollis-Moffatt et al., 2009).

Sex-specific effects: The intronic SLC2A9 signal has a substantially larger effect in women than in men across all cohorts studied, with variance explained reaching ~6% in women versus ~1.2% in men. This sex difference is attributed to estrogen's independent stimulation of renal urate excretion, which amplifies the genetic signal in women but partially offsets it during the reproductive years (Döring et al., 2008)⁸⁸ (Döring et al., 2008).

Practical Actions

Carriers of CC at rs6852441 carry two copies of the risk haplotype tag associated with reduced renal urate clearance from this SLC2A9 signal. The practical implications follow the well-established SLC2A9 urate-management evidence base: eliminate sugar-sweetened beverages (the highest-leverage dietary action for SLC2A9 risk genotypes), reduce dietary purines, and establish a serum uric acid baseline to know where you stand.

The most important gene-environment interaction for this SLC2A9 locus is fructose: sugar-sweetened beverages raise urate through direct hepatic production and also impair GLUT9-mediated renal clearance through competitive inhibition, compounding the genetic risk from the C allele. Eliminating SSBs can reduce serum urate by 0.5–1 mg/dL in susceptible individuals — an effect comparable in magnitude to the genetic contribution of the risk haplotype itself.

Post-menopausal women with CC genotype are particularly exposed because estrogen's uricosuric contribution — which buffers the genetic risk during reproductive years — is withdrawn at menopause, often unmasking clinically significant hyperuricemia for the first time.

Interactions

rs11942223 (SLC2A9 intronic, independent signal): rs11942223 tags a second, genetically independent signal at the SLC2A9 locus (r² = 0.03–0.05 with rs3733591) with its own additive contribution to serum urate. Carrying risk alleles at both rs6852441 and rs11942223 compounds the urate elevation from two independent SLC2A9 regulatory mechanisms.

rs3733591 (SLC2A9 Arg265His missense): The coding variant Arg265His affects GLUT9 transport efficiency directly through a protein-level mechanism independent of rs6852441's regulatory effect. Risk alleles at both compounds the overall SLC2A9-mediated urate retention burden.

rs2231142 (ABCG2 Q141K): ABCG2 reduces intestinal urate secretion through an entirely separate pathway. Carrying risk alleles at rs6852441 (renal reabsorption) and ABCG2 rs2231142 (intestinal secretion) is additive and can produce serum urate above 7 mg/dL even without major dietary provocation.

Fructose and sugar-sweetened beverages: A gene-environment interaction between SLC2A9 genotype and SSB consumption has been documented at this locus: the normally urate-lowering protective allele has its benefit reversed by regular SSB intake, making fructose avoidance important regardless of which allele a person carries, and especially critical for CC risk-allele homozygotes.

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that catalyzes the conversion of androgens to estrogens, the final step in estrogen biosynthesis is expressed in the ovaries, adipose tissue, breast, bone, and brain. Local aromatase activity determines the estrogen microenvironment in hormone-sensitive tissues, and variants that alter CYP19A1 transcription or regulatory activity can shift the androgen-to-estrogen balance in ways relevant to cancer biology, reproductive function, and bone health. rs7167936 sits at chromosome 15 position 51,207,348 (GRCh38) — approximately 709 bp upstream of the annotated CYP19A1 transcription start site and within an intron of the neighboring non-coding RNA gene MIR4713HG. It maps to the CYP19A1 RefSeqGene (NG_007982.1:g.136251T>C), placing it squarely in the regulatory zone that governs aromatase expression in peripheral tissues.

The Mechanism

rs7167936 is classified as an intron variant in the MIR4713HG host gene transcript but lies within the broader CYP19A1 genomic locus. The CYP19A1 gene is on the minus strand of chromosome 15, meaning that the plus-strand coordinate 51,207,348 is upstream of the 3' (coding) end of the gene and near the region containing tissue-specific promoter elements. CYP19A1 is unusual in that it uses at least ten different tissue-specific promoters spread over ~93 kb of upstream sequence, with different promoter elements driving expression in the ovary, adipose tissue, bone, and brain. Variants in this regulatory region can alter which tissues express aromatase, at what level, and in response to which hormonal signals — without changing the protein itself.

rs7167936 has not been directly characterized for transcription factor binding or allele-specific expression, unlike the better-studied rs1062033 (CEBPβ binding) or rs700518 (splicing-related). Its functional significance is inferred from population-level association signals rather than from direct mechanistic studies.

The Evidence

The primary evidence for rs7167936 comes from Darabi et al. 2011²² Darabi et al. 2011
Breast Cancer Research and Treatment — 1,569 Swedish breast cancer patients; rs7167936 associated with histological grade (p=0.010) and tumor size (p=0.005; 1-sided). The study examined genetic variation across the androgen-to-estrogen conversion pathway in relation to tumor characteristics. rs7167936 associations with grade and size persisted when restricted to ER-positive tumors (p=0.008 and p=0.011), consistent with an estrogen-pathway mechanism influencing tumor biology rather than an off-target effect. rs4646 showed the strongest single-SNP associations in the same study, with the common CYP19A1 allele linked to low histological grade and smaller tumor size.

The variant has not been independently replicated for the specific associations with histological grade and tumor size. The evidence base is therefore limited to a single cohort and qualifies as emerging rather than strong. No ClinVar submissions exist, and no pharmacogenomics guidelines reference this variant. The broader CYP19A1 locus harbors multiple variants with stronger and better-replicated associations — rs727479, rs4646, rs10046, rs700518, and rs1062033 — with which rs7167936 may be in partial linkage disequilibrium, though formal LD data are not readily available.

Glubb et al. 2017³³ Glubb et al. 2017
review of CYP19A1 variation and aromatase inhibitor outcomes concluded that rs727479 best captures the CYP19A1 signal for circulating estradiol and that rs4646 (in LD with rs727479) was the only variant replicating across studies for aromatase inhibitor treatment outcomes. The position of rs7167936 near the CYP19A1 regulatory zone suggests it may tag this same haplotype block, though this requires formal confirmation.

Practical Actions

For carriers of the G allele (one or two copies), the evidence base is currently too limited to support specific clinical recommendations independent of the variant's broader CYP19A1 haplotype context. The primary actionable implication is awareness for women with a personal or family history of hormone receptor-positive breast cancer: the Darabi cohort data suggest this locus tags a biological signal influencing breast cancer tumor behavior, though the association is from a single study and the allele-specific direction requires clarification from the full text of the original paper.

Women undergoing surveillance for hormone-sensitive cancers or those with known CYP19A1 haplotype risk should discuss this variant alongside the better-characterized SNPs at the same locus (rs4646, rs10046, rs700518) with their clinician, as haplotype context may provide more interpretive power than any single variant in isolation.

Interactions

rs7167936 resides within the broader CYP19A1 regulatory zone that contains rs700518 (~12 kb upstream), rs1062033 (~12 kb upstream), rs10046 (in the 3'UTR), and rs4646 (in intron 4). These variants form multiple haplotype blocks and their combined effect on aromatase expression has been studied in bone, breast, and endometrium. The association of rs7167936 with breast tumor characteristics in the Darabi cohort was studied in the context of all these variants simultaneously; it is plausible that rs7167936 tags a haplotype shared with one or more of these better-characterized variants, though formal LD mapping at this position is needed.

Every cell in your body needs cholesterol to build membranes and synthesize hormones. To keep blood LDL from accumulating, the LDLR gene¹¹ LDLR gene
Low-density lipoprotein receptor: a cell-surface protein that captures LDL particles circulating in blood and pulls them into cells for degradation, removing them from the bloodstream encodes a receptor that acts like a molecular claw — binding LDL particles at the cell surface, pulling them inside, releasing the LDL into the lysosome for processing, and then recycling back to the surface to repeat the cycle. rs730882094 introduces a single amino acid change at position 316 of this receptor protein — swapping asparagine for serine — within one of the receptor's critical EGF-like repeat domains²² EGF-like repeat domains
EGF precursor homology domain: a structural region of the LDLR that enables acid-dependent release of LDL in the endosome and receptor recycling back to the cell surface. Mutations here often impair LDLR biosynthesis, trafficking to the cell surface, or the conformational switch needed for pH-dependent LDL release. The consequence is impaired receptor processing, reduced LDL clearance, and lifelong elevation of LDL cholesterol — the hallmark of familial hypercholesterolemia (FH).

FH is one of the most common inherited metabolic disorders³³ one of the most common inherited metabolic disorders
Familial hypercholesterolemia affects an estimated 1 in 200–250 individuals globally (heterozygous form), yet fewer than 10% are diagnosed or treated in most countries, but LDLR variant–specific entries like Asn316Ser are rare — gnomAD records only 11 G-allele chromosomes among 1.4 million in the exome database (~0.001%). The variant was classified as Likely Pathogenic⁴⁴ classified as Likely Pathogenic
ClinVar VCV000183103: 4 of 6 expert submissions classify this as Likely Pathogenic for familial hypercholesterolemia; 2 classify as Uncertain Significance. The LP classifications come from the British Heart Foundation LDLR-LOVD database, Color Diagnostics, All of Us Research Program (NIH), and Charité Berlin for familial hypercholesterolemia by multiple independent submitters.

The Mechanism

The LDLR protein consists of several domains: an LDL-binding domain at the N-terminus, followed by EGF precursor homology (EGFPH) repeats A, B, and C that control pH-dependent LDL release and receptor recycling. Asn316 sits within EGF-like repeat A (amino acids 315–354), a region enriched for pathogenic LDLR variants⁵⁵ enriched for pathogenic LDLR variants
Functional studies from ClinVar submitter Merck Research Labs show this variant "interferes with protein transport and significantly affects LDLR biosynthesis or turnover," consistent with the known functional role of EGF-A domain asparagines in receptor folding and glycosylation and one where asparagine residues are known to be important for N-linked glycosylation, protein folding, and intracellular trafficking. Substituting serine at position 316 disrupts these interactions, impairing the receptor's maturation and transport to the cell surface.

The result is a reduced number of functional LDL receptors available to clear circulating LDL particles. LDL accumulates in plasma, depositing in arterial walls over decades and driving accelerated atherosclerosis. In untreated FH heterozygotes (carrying one mutant LDLR allele), LDL-C typically runs 2–4× above population norms from birth — a cumulative atherogenic burden that manifests as premature coronary artery disease, often before the fifth decade of life.

The Evidence

The classification of this variant rests on a combination of evidence:

Functional data: Merck Research Labs functional profiling data in ClinVar documents that Asn316Ser "interferes with protein transport and significantly affects LDLR biosynthesis or turnover" — a non-trivial mechanistic finding even if the full study data are unpublished. Computational predictions are conflicting (SIFT: deleterious; PolyPhen-2: benign), which is common for variants in the EGF domain where the structural context matters more than biochemical similarity scores.

Clinical observations: Five heterozygous carriers in one series⁶⁶ Five heterozygous carriers in one series
ClinVar submitter Molecular Genetics Lab, Centre for Cardiovascular Surgery, Czech Republic — observed 5 individuals aged 22–53 with clinical FH features: hypercholesterolemia, xanthelasma, tendon xanthomas, and corneal arcus (for the closely related Asn316Thr variant at the same codon) presented with classic FH clinical features, strengthening the pathogenic case for this codon.

Disease context: Defesche et al.'s landmark 2017 review⁷⁷ Defesche et al.'s landmark 2017 review
Defesche JC et al. Familial hypercholesterolaemia. Nat Rev Dis Primers, 2017 established that untreated FH confers up to a 13-fold increased risk of coronary heart disease compared to the general population, with event risk accumulating silently from childhood. Nordestgaard et al.'s European Atherosclerosis Society consensus⁸⁸ Nordestgaard et al.'s European Atherosclerosis Society consensus
Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. Eur Heart J, 2013 set adult LDL-C targets below 2.5 mmol/L (≈97 mg/dL) for FH patients and below 1.8 mmol/L (≈70 mg/dL) for those with established coronary disease.

The aggregate classification of Likely Pathogenic (rather than Pathogenic) reflects the relatively small number of independent affected families described to date for this specific allele, and conflicting computational predictions. As data accumulate, reclassification to Pathogenic is possible.

Practical Actions

For heterozygous carriers of rs730882094 G, the key priorities are: (1) confirm LDL-C elevation with a fasting lipid panel, (2) initiate high-intensity statin therapy as early as feasible, (3) cascade-test first-degree relatives, and (4) manage all co-occurring cardiovascular risk factors aggressively.

Statins remain the first-line treatment⁹⁹ Statins remain the first-line treatment
High-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg) reduce LDL-C by 50–55% as monotherapy. Addition of ezetimibe provides a further 15–20% reduction. PCSK9 inhibitors (evolocumab, alirocumab) achieve an additional 50–60% reduction and are indicated when LDL-C target is not achieved with maximum tolerated statin + ezetimibe for FH. Early treatment reduces lifetime atherosclerotic burden. In FH heterozygotes without other risk factors, treatment targets LDL-C below 2.5 mmol/L (97 mg/dL); in those with existing cardiovascular disease, below 1.8 mmol/L (70 mg/dL).

Interactions

LDLR Asn316Ser interacts with other genetic modifiers of LDL metabolism. APOE genotype (rs429358 / rs7412) modulates LDL levels independently — carriers of APOE ε4 alongside an LDLR variant may have even higher LDL than expected from the LDLR mutation alone. PCSK9 gain-of-function variants (e.g., rs28942453 / PCSK9 D374Y) accelerate LDLR degradation and compound the receptor deficit; PCSK9 loss-of-function variants are protective and may blunt FH severity. APOB variants (e.g., rs121908028 / APOB R3527Q) cause a clinically identical FH phenotype through a different mechanism (impaired LDL particle binding rather than receptor dysfunction). Genetic testing panels for FH routinely screen all three genes simultaneously.

When the hepatitis B virus enters the body, the immune system must decide within weeks whether to mount a clearing response or allow the infection to persist for life. That decision hinges heavily on HLA class II antigen presentation¹¹ HLA class II antigen presentation
The process by which antigen-presenting cells — dendritic cells, macrophages, B cells — display viral peptide fragments on MHC class II molecules to CD4+ T helper cells, initiating adaptive immunity. rs7770370 sits within the HLA-DPB1 gene on chromosome 6p21 and marks a haplotype block that controls how efficiently the immune system presents HBV antigens. The G allele at this position tags a low-expression HLA-DP haplotype — carriers produce fewer HLA-DP antigen-presenting complexes, mount weaker T-cell responses to HBV, and face significantly higher odds of chronic infection and vaccine non-response.

The Mechanism

HLA-DP is a heterodimeric surface receptor composed of an alpha chain (HLA-DPA1) and a beta chain (HLA-DPB1), expressed on antigen-presenting cells including the Kupffer cells and dendritic cells of the liver. It binds viral peptide fragments in its groove and displays them to CD4+ T helper cells²² CD4+ T helper cells
The immune cells that coordinate both antibody production by B cells and activation of CD8+ cytotoxic T cells — the two arms of adaptive immunity needed to clear HBV. rs7770370 is an intronic variant in HLA-DPB1 that does not change the protein sequence — instead, it acts as a tag SNP³³ tag SNP
A marker in strong linkage disequilibrium with the functional haplotype; it doesn't cause the effect itself but reliably identifies carriers of the causally relevant low-expression haplotype for a haplotype including the eQTL variants rs3077 (HLA-DPA1 3′ UTR) and rs9277535 (HLA-DPB1 3′ UTR), both of which directly reduce HLA-DP mRNA expression. The G allele at rs7770370 co-segregates with the G allele at rs3077 and the A allele at rs9277535 — the combination associated with the lowest HLA-DPA1 and HLA-DPB1 surface density on liver antigen-presenting cells. With fewer HLA-DP molecules available, HBV peptide display to CD4+ T cells is impaired, T-helper activation is blunted, antibody production against the HBV surface antigen (anti-HBs) is reduced, and cytotoxic T-cell killing of infected hepatocytes is diminished.

The Evidence

Wu et al. (2015)⁴⁴ Wu et al. (2015)
SNP rs7770370 in HLA-DPB1 loci as a major genetic determinant of response to booster hepatitis B vaccination. J Gastroenterol Hepatol performed the first GWAS specifically focused on rs7770370, studying 15- to 18-year-olds who had received primary HBV vaccination in infancy but failed to maintain protective antibody levels. Among HLA-DP candidate SNPs in a 47 kb block, rs7770370 was the sentinel signal: AA homozygotes had an adjusted odds ratio of just 0.095 (CI 0.030–0.307) for vaccine non-response relative to GG homozygotes — a greater than 10-fold difference — while AG heterozygotes showed a 2-fold advantage (OR 0.524). This quantified the G allele as the dominant genetic driver of long-term vaccine failure in this population.

Roh et al. (2016)⁵⁵ Roh et al. (2016)
HLA-DP variants and hepatitis B vaccine responsiveness in Korean infants. Vaccine extended the finding to 290 infants (the primary vaccination setting), showing that the AA genotype was associated with vaccine response (relative risk 2.5, p=0.033) and with high-titer response specifically (RR 2.7, p<0.001). The A allele was significantly more frequent in responders (p<0.01), confirming the genotype predicts immunogenicity from the very first vaccination series.

For chronic HBV infection susceptibility, Huang et al. (2020)⁶⁶ Huang et al. (2020)
Taiwan Biobank GWAS of 15,352 HBV-exposed participants. Aliment Pharmacol Ther identified rs7770370 as the single most significant HLA class II signal for HBV chronicity (P=2.73×10⁻³⁵, Pcorrected <8.6×10⁻⁸). The HLA-DPB1*05:01 allele — in strong LD with the G allele — conferred OR 1.61 (CI 1.29–2.01) for chronic HBV. In a Thai GWAS, Ashouri et al. (2022)⁷⁷ Ashouri et al. (2022)
Genome-wide Association Study for Chronic Hepatitis B in the Thai Population. Front Genet independently replicated the association (p=7.71×10⁻¹⁰, OR=0.49 for the protective A allele). The association is present across Asian, European, and mixed-ancestry cohorts, though the G allele is far more common in populations with historically high HBV endemicity — about 46–54% in East Asians and Africans versus only 13% in Europeans — a pattern consistent with ongoing selection pressure from the virus.

Practical Actions

The key clinical implication is twofold: vaccine response and infection susceptibility. G-allele carriers — especially GG homozygotes — are at substantially higher risk of failing to develop protective antibodies after standard HBV vaccination, and of progressing to chronic infection if exposed. The appropriate actions are checking post-vaccination antibody titres and, for those with exposure risk, baseline serology and follow-up for signs of chronicity.

For those already identified with chronic HBV infection, the HLA-DP haplotype also predicts treatment response dynamics — AA haplotype carriers have better HBsAg seroclearance during nucleot(s)ide analogue therapy, making genotype relevant to hepatologist treatment planning.

Interactions

rs7770370 is part of the same HLA-DP haplotype block as rs3077 (HLA-DPA1 3′ UTR) and rs9277535 (HLA-DPB1 3′ UTR). These three variants tag a low-expression haplotype that produces reduced HLA-DPA1 and HLA-DPB1 mRNA. The combined protective haplotype (A allele at rs3077 and A allele at rs9277535) shows a stronger additive protective effect against chronic HBV (OR 0.57 in Indonesian replication, CI 0.36–0.92) than either variant alone. Profiling all three SNPs together provides the most complete picture of HLA-DP expression and HBV susceptibility in a given individual. Each additional G allele across this haplotype incrementally reduces HLA-DP surface density and immune clearance capacity.

Deep inside ovarian theca cells, a protein better known for its role in cellular housekeeping has been implicated in one of the most common endocrine disorders in women of reproductive age. DENND1A¹¹ DENND1A
DENN domain containing 1A; a guanine nucleotide exchange factor for RAB35 involved in clathrin-mediated endocytosis and receptor recycling sits at chromosome 9q33.3, a locus that genome-wide association studies have now replicated across multiple ethnicities as a polycystic ovary syndrome (PCOS) susceptibility region. The rs7852296 variant is an intronic tag SNP within this locus — the A allele marks a haplotype associated with elevated DENND1A expression in the tissues that produce androgens.

The Mechanism

DENND1A generates two splice variants. The canonical transcript (V1) participates in normal endosomal recycling. The shorter splice variant, DENND1A.V2²² DENND1A.V2
the truncated isoform that retains the DENN domain but lacks the long C-terminal tail of V1; overexpressed in PCOS theca cells at both mRNA and protein level, accumulates selectively in PCOS-affected theca cells. When DENND1A.V2 is overexpressed experimentally in normal theca cells, CYP17A1 — the rate-limiting enzyme for androgen synthesis — is markedly upregulated, recapitulating the excess androgen production that characterises PCOS.

A complementary mechanism was identified in granulosa cells. Dou et al. 2024³³ Dou et al. 2024
DENND1A desensitizes granulosa cells to FSH by arresting intracellular FSHR transportation. Sci China Life Sci 67:1587–1600 demonstrated that elevated DENND1A expression disrupts the intracellular trafficking of the follicle-stimulating hormone receptor (FSHR), promoting its internalization while inhibiting recycling back to the cell surface. The net effect is FSH resistance — the granulosa cells cannot mount a normal response to the gonadotropin that drives follicle maturation. Transgenic mice overexpressing DENND1A showed reduced fertility, irregular cycles, and elevated testosterone, mirroring the human PCOS phenotype.

The causal chain from locus to disease was further anchored by a 2025 Nature Communications study: Sankaranarayanan et al. 2025⁴⁴ Sankaranarayanan et al. 2025
Gene regulatory activity associated with PCOS revealed DENND1A-dependent testosterone production. Nat Commun 16:7123 used STARR-seq to map regulatory elements within the DENND1A locus, identifying four variants with allele-specific activity that function as expression QTLs. CRISPR epigenome editing confirmed that activating these regulatory elements raises DENND1A expression and, downstream, testosterone production in adrenal cell models.

The Evidence

The DENND1A locus at 9q33.3 was first identified as a PCOS susceptibility region in Chinese cohorts and subsequently replicated in European populations. Goodarzi et al. 2012⁵⁵ Goodarzi et al. 2012
Replication of association of DENND1A and THADA variants with PCOS in European cohorts. J Med Genet 49:90–95 tested seven SNPs across LHCGR, THADA, and DENND1A in nearly 2,500 European PCOS cases and controls. The rs10818854-A allele showed the strongest DENND1A signal (combined OR 1.87, 95% CI 1.48–2.35, p=9.8×10⁻⁸; BMI-adjusted OR 2.02, p=6.5×10⁻⁸). The same paper noted that rs7852296, a neighbouring intronic variant in the same gene, had been associated with the personality dimension of Persistence in a genome-wide scan (p=9×10⁻⁶), illustrating that DENND1A regulatory variation influences diverse phenotypes across tissues.

A large European meta-analysis — Day et al. 2018⁶⁶ Day et al. 2018
Large-scale GWAS meta-analysis of PCOS suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813 — combining 10,074 PCOS cases and 103,164 controls confirmed DENND1A as one of 14 replicated PCOS loci (rs9696009-A, beta 0.20, p=10⁻¹¹). Evidence that rare DENND1A noncoding variants contribute beyond common SNPs comes from whole-genome sequencing of PCOS families: Dapas et al. 2020⁷⁷ Dapas et al. 2020
Distinct subtypes of PCOS with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med 17:e1003043 showed that carriers of rare DENND1A deleterious variants were significantly enriched in the reproductive PCOS subtype (high LH, normal BMI), underscoring that the locus exerts its effect primarily through the reproductive axis rather than the metabolic one.

The variant-level evidence for rs7852296 itself is sub-genome-wide-significant for PCOS (it appears in the GWAS Catalog as a DENND1A association with beta 0.17). Its clinical utility derives from its position as a tag SNP marking the broader DENND1A susceptibility haplotype, which has been replicated at genome-wide significance in multiple independent cohorts.

Practical Actions

Because the DENND1A mechanism is reproductive rather than metabolic, monitoring is most valuable in women with clinical signs of PCOS — irregular cycles, acne, excess hair growth, or difficulty conceiving. Elevated androgen levels (free testosterone, DHEAS) are the biomarker most directly connected to DENND1A pathway activity. Anti-Müllerian hormone (AMH) reflects the follicular arrest that FSH resistance produces, and elevated AMH is a hallmark of the reproductive PCOS subtype enriched for DENND1A variants.

Inositol supplementation — specifically myo-inositol and D-chiro-inositol — acts downstream of FSH signalling to improve ovarian sensitivity and has specific evidence in PCOS with FSH resistance. Spearmint tea has documented anti-androgenic activity in PCOS (reduces free testosterone via LH/FSH modulation) without systemic anti-androgen side effects.

Metformin and GLP-1 receptor agonists address the metabolic PCOS phenotype more than the reproductive one and are therefore less specifically targeted to the DENND1A pathway.

Interactions

The strongest known gene-gene interaction at the PCOS susceptibility level involves DENND1A together with THADA (rs13429458) and LHCGR (rs13405728). Each locus contributes independently to PCOS risk in European cohorts (Goodarzi 2012). Individuals carrying risk alleles at all three loci would represent the highest polygenic burden from this trio of loci, but no published compound effect size exists for the triple combination.

The reproductive PCOS subtype (enriched for DENND1A variants) overlaps with elevated LH pulsatility — making GNRH/LH axis variants (LHCGR rs13405728) the most biologically coherent interaction partner. The combined effect of impaired FSHR recycling (DENND1A) and altered LH receptor signalling (LHCGR) on follicular dynamics warrants investigation as a compound interaction.

Beneath the surface of allergic asthma, rhinitis, and eczema lies a shared distress signal: IL-33¹¹ IL-33
Interleukin-33, an alarmin cytokine stored in the nuclei of epithelial cells lining the airways, gut, and skin; released upon cell damage or allergen exposure, it binds the ST2 (IL1RL1) receptor on mast cells, ILC2 innate lymphoid cells, and eosinophils to initiate type-2 inflammation. rs1342326 sits approximately 25 kilobases upstream of the IL33 transcription start site on chromosome 9. The C allele acts as a gain-of-expression variant: carriers produce more IL-33 mRNA in bronchial epithelium, meaning every allergen challenge, viral rhinitis, or pollutant exposure generates a louder alarm. The GABRIEL consortium's genome-wide association study²² GABRIEL consortium's genome-wide association study
Moffatt et al. 2010, N=26,475; p=9×10⁻¹⁰ first established this SNP at genome-wide significance for asthma risk, and it has since been replicated across multiple European, Middle Eastern, and pediatric cohorts for asthma, allergic rhinitis, and hay fever.

The Mechanism

rs1342326 is a regulatory (eQTL) variant³³ regulatory (eQTL) variant
Expression quantitative trait locus — a variant that influences how much RNA is made from a nearby gene, without changing the protein sequence in the IL33 upstream regulatory region. The C allele is associated with measurably higher serum IL-33 protein concentrations in carriers, confirmed in the Tunisian pediatric cohort (Charrad et al. 2018)⁴⁴ (Charrad et al. 2018)
PMID 28985997. Higher constitutive IL-33 output means that the ST2/IL1RL1 receptor system — which mediates type-2 immune activation on mast cells, ILC2s, and eosinophils — is chronically primed above population baseline.

A second immune mechanism emerges from the PASTURE/EFRAIM birth cohort: C allele carriers show significantly reduced regulatory T cells (Tregs)⁵⁵ regulatory T cells (Tregs)
CD4+CD25+FOXP3+ cells that suppress immune overactivation; lower Treg frequency is associated with impaired allergen tolerance and higher atopic disease risk and elevated SOCS3 mRNA expression, which negatively correlates with Treg abundance (Schröder et al. 2016). This suggests that the rs1342326-C allele not only increases IL-33 output but also undermines the immune regulatory circuitry that normally limits Th2 responses — a compounding effect that helps explain the variant's association with multiple atopic phenotypes simultaneously.

The Evidence

The landmark GABRIEL GWAS⁶⁶ GABRIEL GWAS
Moffatt et al. NEJM 2010; 10,365 cases + 16,110 controls from European populations; genome-wide significance p=9×10⁻¹⁰ placed rs1342326 at the IL33 locus as one of the reproducible asthma risk signals, alongside IL1RL1 (ST2 receptor), HLA-DQ, and ORMDL3/GSDMB. The C allele risk allele frequency of ~16% in Europeans means a substantial fraction of the population carries at least one copy.

Pediatric longitudinal data strengthens the causal interpretation. In the Finnish post-bronchiolitis cohort⁷⁷ post-bronchiolitis cohort
Korppi et al. Acta Paediatr 2020; 141 children followed to ages 6 and 12, AC/CC carriers showed OR 2.17 for allergic rhinitis at age 6.4, rising to OR 3.23 at age 11.7 — a signal that strengthens over time, consistent with the progressive nature of atopic march. Notably, 22.5% of variant carriers required inhaled corticosteroids by age 6 versus only 8.9% of AA homozygotes.

In an Iranian adult case-control study (Matloubi et al. 2020⁸⁸ (Matloubi et al. 2020
126 asthmatics + 300 controls), the CC genotype carried OR 2.50 (95% CI 1.33–4.69) for asthma and was specifically associated with the atopic, eosinophil-elevated subtype. The elevated peripheral eosinophil counts in CC carriers confirm that the IL33-C eQTL effect flows through the IL-33→ST2→eosinophil axis, producing the quantitative biomarker signature consistent with type-2 high asthma.

An important pharmacogenomic signal comes from a Canadian pediatric exacerbation study⁹⁹ Canadian pediatric exacerbation study
Tse et al. Pediatr Pulmonol 2019; 491 children with acute moderate-to-severe asthma exacerbations: C allele carriers experienced significantly worse acute outcomes (management failure OR 0.52 for AA vs other genotypes), with higher rates of hospitalization and prolonged emergency care — suggesting that elevated IL-33 signaling during acute viral triggers drives more severe exacerbation phenotypes that are harder to control acutely.

Practical Implications

The C allele's mechanism — elevated IL-33 output → chronically primed ST2/eosinophil axis — points to two monitoring priorities: (1) tracking the downstream eosinophil and airway inflammation burden with FeNO and blood eosinophil count, and (2) being alert to the atopic march trajectory, particularly after early-life respiratory infections. IL-33 itself is now a pharmaceutical target: itepekimab (Dupixent's companion anti-IL-33 antibody) and tezepelumab (anti-TSLP, which synergises with IL-33 upstream) both mechanistically converge on the pathway amplified by this variant. Carriers with moderate-to-severe asthma are biologically well-matched to biologics that interrupt upstream type-2 signaling.

Interactions

rs1342326 (IL33 ligand, elevated expression) and rs1420101 (IL1RL1/ST2 receptor, reduced sST2 decoy expression) represent two nodes of the same IL-33 signaling axis. The rs1420101-T allele lowers circulating soluble ST2 — the natural IL-33 decoy receptor — so IL-33 is less buffered. Carrying C at rs1342326 and T at rs1420101 compounds both ends: more IL-33 released AND less decoy to intercept it. This interaction is documented in the literature on the IL-33/ST2 pathway and is captured in compound actions in this database. The related IL33 variant rs992969 tags a second upstream regulatory position also associated with increased IL33 expression; compound carriers of both IL33 risk alleles carry additive expression burden.

Clusterin (CLU), also known as apolipoprotein J, is the third strongest known genetic risk factor for late-onset Alzheimer's disease after APOE and BIN1. It is a secreted molecular chaperone that binds misfolded proteins — including amyloid-beta (Aβ) — and escorts them out of the brain across the blood-brain barrier. The rs1532278 variant sits in an intronic regulatory region of the CLU gene and is one of the most studied and most robustly replicated Alzheimer's risk loci in the entire human genome.

The Mechanism

CLU exerts its neuroprotective effect through two overlapping pathways. First, secreted clusterin forms stable complexes with Aβ and facilitates its clearance from the brain across the blood-brain barrier¹¹ blood-brain barrier
the highly selective barrier between brain tissue and circulating blood via the LRP2 receptor. Second, CLU inhibits Aβ oligomerization and aggregation directly, preventing the formation of the toxic soluble oligomers that damage synapses before plaques ever appear.

Rs1532278 is located in an intronic open chromatin region — a regulatory element — in glutamatergic (excitatory) neurons. A 2025 study using CRISPR editing of human iPSC-derived neurons showed that only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons²² only rs1532278 among all CLU locus variants sits in an accessible chromatin region in neurons
Zhao et al., Molecular Neurodegeneration, 2025. The T allele creates stronger binding for the ISL2 transcription factor, retaining approximately 80% more binding capacity than the C allele. This drives elevated neuronal CLU transcription and secretion.

The protective T allele's downstream effect is measurable: T/T carriers show approximately 40–50% higher CLU mRNA expression in glutamatergic neurons compared to C/C carriers, along with greater dendritic complexity, enhanced synaptic marker expression, and higher neuronal firing frequency. Elevated neuronal CLU promotes neuron-to-astrocyte lipid transfer, increasing astrocytic lipid droplet accumulation and fine-tuning glutamate clearance — a lipid-mediated neuron-glia communication pathway that supports neuronal resilience.

The Evidence

CLU was first identified as an Alzheimer's risk locus in the landmark 2009 Harold et al. GWAS³³ 2009 Harold et al. GWAS
Harold et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009 (5,964 cases + controls, OR = 0.86 for the protective haplotype). Rs1532278 is in near-complete linkage disequilibrium with rs11136000 (r² = 0.95, D′ = 0.99), the originally reported CLU lead SNP — but rs1532278 shows slightly stronger association with ventricular expansion and Aβ deposition, suggesting it sits closer to the true causal variant.

A 2010 meta-analysis confirmed the CLU association across 15,000+ individuals⁴⁴ confirmed the CLU association across 15,000+ individuals
Jun et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci. Archives of Neurology, 2010 (OR = 0.91, 95% CI 0.85–0.96), and showed the CLU effect is independent of APOE ε4 status — unlike PICALM, whose effect is largely confined to ε4 carriers. The 2025 functional study reported an even more significant signal at rs1532278 specifically: OR = 0.905 with p = 3.2 × 10⁻³³ in a large meta-GWAS.

Plasma clusterin levels serve as a biomarker for AD progression. Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6⁵⁵ Elevated plasma clusterin in MCI predicted progression to AD with HR = 18.6
Jongbloed et al. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. J Alzheimers Dis, 2015 and correlated with faster cognitive decline (r = −0.38). Notably, C/C homozygotes have higher plasma clusterin concentrations, reflecting a compensatory upregulation in response to reduced brain clearance efficiency.

Practical Actions

Rs1532278 C/C and C/T carriers do not have a pathogenic variant — this is a common risk-modifying SNP, not a disease-causing mutation. The C allele is carried by approximately 86% of people in some form (C/C or C/T). Practical focus for C-allele carriers is on lifestyle factors that support the CLU-Aβ clearance pathway: omega-3 fatty acids support neuronal membrane integrity and reduce neuroinflammation at CLU-relevant pathway nodes; aerobic exercise increases CLU expression in hippocampal tissue; and avoiding chronic sleep deprivation is specifically relevant because Aβ clearance via the glymphatic system is maximally active during deep sleep — a pathway that overlaps functionally with CLU-mediated BBB clearance.

Monitoring cognition from midlife is meaningful for C/C homozygotes: baseline cognitive assessments with standardized tools (MoCA or MMSE) in the 40s–50s provide early-change detection before symptoms are clinically apparent.

Interactions

The strongest known interaction is with APOE. APOE ε4 and CLU risk alleles both impair Aβ clearance through related but distinct mechanisms — APOE via direct Aβ binding competition and receptor-mediated clearance at LRP1, CLU via LRP2 — and carriers of both risk alleles show amplified ventricular expansion rates and accelerated Aβ accumulation in imaging studies. This CLU × APOE interaction is documented in the literature and is a strong candidate for a compound action (see interaction candidates below).

The CLU locus also contains rs9331888 (exon 1) and rs7982 (exon 5), which affect alternative splicing of CLU transcripts in a sex-dependent manner. These three variants are in partial LD and tag different functional effects within the same gene — rs1532278 affects transcription in neurons, rs9331888 affects splicing, and rs7982 affects intron retention primarily in females.

Deep inside chromosome 9 lies a short stretch of DNA — the 9p21.3 locus — that carries some of the most replicated disease associations ever discovered. Within this region sits ANRIL (antisense non-coding RNA in the INK4 locus), a long non-coding RNA that acts as a molecular volume knob for cellular senescence. Variants in ANRIL are associated, in the same region of the genome, with coronary artery disease, myocardial infarction, type 2 diabetes, intracranial aneurysm, glioma, and physical aging — a concentration of GWAS hits rare in the human genome¹¹ a concentration of GWAS hits rare in the human genome
Pasmant E et al. ANRIL, a long noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 2011..

rs1537373 is an intronic variant within the ANRIL gene itself (CDKN2B-AS1), positioned at chromosome 9, base 22,103,342 on the GRCh38 reference. It is one of several independent tag SNPs at this locus, each capturing a partially distinct signal. The T allele at rs1537373 is the risk allele for myocardial infarction and brain aneurysm, while the locus as a whole — through nearby variants in strong linkage disequilibrium — also confers type 2 diabetes susceptibility.

The Mechanism

ANRIL is transcribed antisense to three protein-coding genes packed tightly together at 9p21.3: CDKN2B (encoding p15INK4b), CDKN2A (encoding p16INK4a and p14ARF), and MTAP. p15 and p16 are cyclin-dependent kinase inhibitors²² cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4 and CDK6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence. As cells accumulate damage or age, rising p16 and p15 levels lock them in a permanent growth arrest — senescent "zombie" cells³³ senescent "zombie" cells
Senescent cells remain metabolically active but stop dividing, secreting pro-inflammatory cytokines (the SASP) that progressively damage surrounding tissue that fuel atherosclerosis and impair tissue regeneration.

ANRIL regulates CDKN2A/CDKN2B expression in cis by recruiting PRC2 (Polycomb Repressive Complex 2)⁴⁴ PRC2 (Polycomb Repressive Complex 2)
PRC2 deposits repressive H3K27me3 histone marks that silence nearby genes; loss of PRC2 recruitment allows CDKN2A/2B to be more highly expressed, accelerating senescence to silence the INK4 locus. Variants at rs1537373 alter the expression of specific ANRIL isoforms, shifting the balance toward either more or less CDKN2A/2B expression in vascular and pancreatic tissues. In vascular smooth muscle cells (VSMCs), elevated p16/p15 accelerates VSMC senescence and plaque-forming behavior, driving atherosclerosis. In pancreatic beta cells, the same pathway reduces proliferative capacity and total beta-cell mass over decades, impairing insulin production.

Notably, the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping⁵⁵ the cardiovascular and T2D-associated SNPs within the 9p21 locus are largely non-overlapping
Kong et al. ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease. Front Endocrinol. 2018. PMID:30087655, suggesting distinct ANRIL isoforms and regulatory elements govern each disease phenotype — with rs1537373 primarily tagging the cardiovascular signal at this multi-trait locus.

The Evidence

The 9p21 locus entered the cardiovascular genetics literature with force in 2007. Helgadottir et al.⁶⁶ Helgadottir et al.
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007. PMID:17478679 showed that approximately 21% of the population is homozygous for the risk variant at 9p21, and their estimated MI risk is 1.64 times that of noncarriers — rising to 2.02-fold for early-onset MI. The population attributable risk from this single locus was estimated at 21% for general MI and 31% for early-onset disease.

At the same time, Samani et al. 2007⁷⁷ Samani et al. 2007
Genomewide association analysis of coronary artery disease. NEJM 2007. PMID:17634449 confirmed the 9p21 region (lead SNP rs1333049, in strong LD with rs1537373) as the single strongest genetic risk locus for coronary artery disease ever identified, with a per-allele OR of 1.36 (95% CI 1.27–1.46). These findings have been replicated consistently across dozens of independent cohorts.

GWAS Catalog data specific to rs1537373 shows genome-wide significant associations with myocardial infarction (p = 2×10⁻⁷¹), brain aneurysm (p = 3×10⁻²² to 3×10⁻²⁹), coronary artery calcification (p = 4×10⁻¹¹), heart failure (p = 2×10⁻¹²), and LDL cholesterol elevation (p = 5×10⁻¹⁷).

The T2D connection at this locus was established by three concurrent 2007 GWAS that identified nearby 9p21 variants (rs10811661, rs564398) as independent T2D susceptibility signals. A meta-analysis by Cugino et al.⁸⁸ meta-analysis by Cugino et al.
Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis 2012. PMID:21315566 across 22 studies (38,455 T2D cases, 60,516 controls) confirmed per-allele OR 1.24 (P < 10⁻¹⁵) for the primary 9p21 T2D signal, with 15% population attributable risk in Caucasians.

Practical Actions

The GWAS catalog T-allele associations for rs1537373 cover both acute cardiovascular events (MI, aneurysm) and metabolic disease (T2D, LDL). Actions at this locus target:

• Reducing atherosclerotic plaque progression through dietary and monitoring strategies
• Catching asymptomatic coronary artery disease early, when intervention is most effective
• Managing the metabolic stressors that exhaust beta-cell reserves

A critical finding: Do et al. 2012⁹⁹ Do et al. 2012
INTERHEART and FINRISK study of diet-gene interaction at 9p21. PMID:22022235 showed that among those with the highest "prudent diet" scores (rich in raw vegetables and fruits), the 9p21 genetic risk for MI was effectively abolished. Among those with low prudent diet scores and two risk alleles, MI risk was doubled. The dietary interaction at this locus is one of the strongest gene-diet interactions in cardiovascular genetics.

Interactions

rs1537373 is in strong linkage disequilibrium with the primary CAD variant rs1333049 and with the T2D variants rs10811661 and rs564398 — all within the same ~200 kb stretch of 9p21.3. These variants together capture overlapping but distinct regulatory signals within the ANRIL locus. Carrying risk alleles at multiple 9p21 positions compounds risk across cardiovascular and metabolic phenotypes through shared cellular senescence biology.

The longevity-associated rs2811712 within ANRIL (covered in the Longevity & Aging category) represents a further independent signal at the same gene, primarily associated with age-related physical function and frailty — illustrating how different ANRIL isoforms modulate distinct tissue-specific aspects of aging.